Mipsagargin: Completed Phase II enrollment

GenSpera completed enrollment of 25 patients who had previously progressed on or who were intolerant of Nexavar sorafenib in an open-label, U.S. Phase II trial evaluating 40 mg/m 2 IV mipsagargin on days 1-3 of each 28-day cycle. Mipsagargin is also in Phase II testing to treat glioblastoma multiforme (GBM) and prostate cancer, with a Phase II trial in renal cell carcinoma (RCC) expected to begin this quarter. ...